FBM assisted Bio-Connect Group shareholders in the sale of the company to AddLife.
Bio-Connect Group (“BioConnect”) is a distributor within the Healthcare sector with operations in the Benelux countries and locations in the Netherlands and Belgium. BioConnect has a large portfolio of products for medical screening and diagnostics and sells these mainly to research companies within the sectors Diagnostics, Food, Pharma and Veterinary. Bio-Connect customers are primarily universities and hospital laboratories, as well as private and government-funded research organizations.
AddLife is a listed Swedish Medtech company operating in the European market. AddLife owns and acquires market leading companies in niche segments with offerings primarily focused on the healthcare sector from research to medical care. AddLife shares have been listed since 2016 on Nasdaq Stockholm, Mid Cap. It is headquartered in Stockholm.
The acquisition of BioConnect by AddLife strengthens AddLife’s presence in the Benelux and provides opportunities for cooperation with other companies in their portfolio in Europe that are active in the same product segment. The Benelux countries are an attractive Life Science market in Europe, where AddLife has been active in Medtech for many years. AddLife continues its expansion in Europe through the acquisition of BioConnect.
FBM acted as counsel to seller.